A General Practitioner approach to canine lymphoma (NYV 2024)

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor(Laverdia-CA1).  We will review SINE mechanism of action along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval ofLaverdia-CA1.  We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor their lymphoma patient on verdinexor, including how to address any potential adverse events.

• How SINE drugs work and why they are different
• When to consider treatment with verdinexor
• How to administer verdinexor
• Verdinexor side effect profile and appropriate treatment options
• Safe handling guidelines for verdinexor

Canine

Presented by Philip J. Bergman, Director, Clinical Studies - Mars Veterinary Health & VCA

Presented at New York Vet 2024

Please note this session is not RACE-approved but you can still earn a CE certificate.